TrialCardiovascular diabetology2024

Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Marina Pourafkari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.